BNP-targeted nano antibody as well as preparation method and application thereof

By developing nano-antibody targeting BNP and its preparation method, the problems of high cost and poor heat resistance of traditional monoclonal antibodies in BNP detection are solved, and the specific binding of high affinity to BNP protein is achieved, which is suitable for rapid detection kits , provides efficient and accurate diagnostic tools.

CN118930651APending Publication Date: 2024-11-12NATIONAL INSTITUTE OF METROLOGY CHINA +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411021519.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing BNP detection kits on the market use the traditional monoclonal antibody diabody sandwich method to detect defects such as high cost, poor heat resistance and unsuitable for small molecule sample detection, making it difficult to meet the needs of efficient, fast and accurate in vitro diagnosis.

Method used

A nano-antibody targeting BNP and its preparation method were developed. High affinity and high affinity and BNP protein-bound nano-antibodies.

Benefits of technology

A high-affinity and strong specificity nano-antibody was obtained, which can effectively bind BNP in vitro, and is suitable for the development of rapid detection kits. It provides efficient and accurate diagnostic tools, with important commercial value and clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930651A_ABST
    Figure CN118930651A_ABST
Patent Text Reader

Abstract

The invention discloses a nano antibody for targeting BNP (Brain Natriuretic Peptide) as well as a preparation method and application of the nano antibody. The amino acid sequences of CDR1, CDR2 and CDR3 of the nano antibody are respectively shown as SEQ ID NO: 1-3. The preparation method comprises the following steps: (1) constructing a prokaryotic expression vector and expressing recombinant protein by using an escherichia coli prokaryotic expression system; (2) carrying out alpaca immunization by utilizing the prepared recombinant protein to prepare a nano antibody library; (3) performing solid-phase panning of the nano antibody through a phage display system; (4) carrying out sequencing to obtain a nano antibody sequence, and then carrying out prokaryotic expression and identification; and (5) carrying out Western and Biacore identification to obtain the nano antibody which is combined with the BNP protein in a high affinity manner. The high-affinity nano antibody targeting the BNP is obtained, a tool can be provided for clinical disease diagnosis and treatment through in-vitro mass expression and transformation, and the high-affinity nano antibody has important commercial value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nano antibodies, and in particular to a nano antibody targeting BNP and a preparation method and application thereof. Background Art

[0002] Heart failure refers to the inability to adequately discharge venous blood from the heart due to impairment of the heart's systolic or diastolic function, which causes the ventricles to be overloaded and gradually expand to increase ejection volume. This ventricular expansion also increases the pressure inside the ventricles. Heart failure may lead to a variety of complications such as pulmonary edema, arrhythmia, and renal impairment, which can seriously affect the patient's health and even lead to death. The prevalence of heart failure and the economic burden it brings have had a serious impact on clinical and public health.

[0003] When the heart expands due to pressure or ventricular wall overload, the gene encoding BNP will be activated in the cardiomyocytes. After the coding gene is activated, preproBNP with a length of 134 amino acid residues will be expressed in the cells. The signal peptide of preproBNP is then removed to form proBNP, which is further cleaved into BNP and NT-proBNP and released into the peripheral circulation. BNP is composed of 32 amino acids with a molecular weight of 3.4kDa, which contains a disulfide bond formed by a pair of cysteines. The concentration of BNP in the blood of patients with heart failure is proportional to the severity of the disease. The detection of BNP in the blood has been widely used in the evaluation of suspected heart failure patients and the evaluation of the severity of the disease.

[0004] Currently, the BNP detection kits on the market use the double antibody sandwich method of traditional monoclonal antibodies. However, traditional monoclonal antibodies have defects in in vitro diagnostic kits, such as high cost, poor heat resistance, and unsuitability for small molecule sample detection due to their large size.

[0005] In 1989, researchers discovered a heavy chain antibody variable region that originated from camelids and naturally lacked light chains. The molecular weight is only 15KD, which is 1 / 10 of the molecular weight of conventional antibodies. Its protein crystal structure is 4nm long and 2.5nm in diameter. It is the antibody with the smallest known molecular weight, so it is called a nano antibody. Compared with traditional antibodies, nano antibodies have a longer active binding region, with up to 16-18 amino acids, and have stronger temperature stability and organic solvent tolerance. Some of them can also tolerate proteases and a wider range of acid and base (traditional antibodies can only tolerate pH 6-9, while nano antibodies can tolerate pH 2-11). In addition, nano antibodies are prepared by engineered bacterial expression, which is different from the hybridoma cell preparation method of traditional antibodies. Therefore, they also have the advantages of easy expression and easy genetic engineering. Based on these advantages, nano antibodies have become a powerful tool for the development of efficient, rapid and accurate in vitro diagnostic kits, bringing innovative opportunities for medical testing and disease diagnosis.

[0006] In summary, finding a highly specific and high-affinity anti-BNP nanoantibody has become one of the important research directions in this field. Summary of the invention

[0007] The purpose of the present invention is to provide a nano antibody targeting BNP and a preparation method and application thereof, so as to meet the production demand and application of anti-BNP nano antibodies and provide a tool for developing a nano antibody BNP rapid detection kit.

[0008] The amino acid sequence of the BNP nanobody obtained by the present invention is:

[0009] A nano antibody targeting BNP, wherein the amino acid sequences of its CDR1, CDR2 and CDR3 are CDR1: GRTFGRMG, CDR2: SIFWSSGGAIYADSVKG, and CDR3: ADTPPLGKYDY, as shown in SEQ ID NOs: 1-3, respectively.

[0010] Furthermore, the amino acid sequence of the Nanobody is

[0011] QLQLVESGGGLVQAGDSLRLSCAASGRTFGRMGWFRQAPGKDREWVASIFWSSGGAIYAD

[0012] SVKGRFTISRDNAKNTAYLQMNRLKPEDTAAYYCAADTPPLGKYDYWGQGTQVTVSSAH HSEDPS, as shown in SEQ ID NO: 4.

[0013] The method for preparing the nanoantibody targeting BNP of the present invention comprises the following steps:

[0014] (1) constructing a prokaryotic expression vector and expressing the recombinant protein using the Escherichia coli prokaryotic expression system;

[0015] (2) using the prepared recombinant protein to immunize alpacas to prepare a nanoantibody library;

[0016] (3) Solid-phase panning of nanobodies using a phage display system;

[0017] (4) obtaining the nanobody sequence by sequencing and then performing prokaryotic expression and identification;

[0018] (5) The nanoantibodies with high affinity binding to BNP protein were obtained through Western and Biacore identification.

[0019] Among them, the step (1) specifically comprises the following steps: using the pGEM-NPPB plasmid as a template to amplify the target gene, recovering the target gene by enzyme digestion and then connecting it with the PET32a vector to construct a prokaryotic expression vector PET32a-BNP-6his, extracting a large amount of plasmid after successful sequencing, transforming it into Rosetta (DE3 competent cells), picking bacteria, shaking the bacteria until the OD value of the bacterial solution is 0.6, inducing expression with IPTG at a final concentration of 0.5 mM at 16°C for 11 hours, centrifuging, discarding the supernatant, and ultrasonically treating the bacterial pellet, then using Ni Sepharoseexcel affinity chromatography filler to purify the target protein, verifying it by SDS-PAGE and Western-blot, and using the protein concentration as an immunogen after determination, and storing it at -80°C for later use.

[0020] Wherein, the step (2) is specifically as follows:

[0021] 1) Preparation of immunogen: The purified BNP recombinant protein was mixed with Freund's adjuvant for emulsification, and the homogeneous mixture formed by the emulsification of antigen and adjuvant was stored at 4°C for future use;

[0022] 2) Alpaca immunization: Select the alpacas and ensure that the animals are suitable. After recording the ear number, start the immunization experiment; inject subcutaneously on the left and right sides of the alpaca's buttocks each time, inject 2 points on each side, and inject 0.4mL of emulsified antigen at each point; observe for half an hour after immunization to confirm that the alpaca is in good condition and has no discomfort symptoms; immunize once every 2 weeks, for a total of 4 immunizations;

[0023] 3) Blood collection: Blood was collected from the alpaca's neck vein before each immunization. 10 mL of blood was collected each time, and the serum was separated and stored at -80°C for later use. 100 mL of peripheral blood was collected 5 days after the last immunization to separate lymphocytes.

[0024] 4) Lymphocyte separation: first add 5 mL of cell separation solution to a 15 mL centrifuge tube, then slowly add 5 mL of blood; be careful and slow when adding blood to prevent mixing of blood and separation solution, centrifuge at 400 g for 30 min, carefully aspirate the cotton-like upper immune cells in the middle into a new 15 mL centrifuge tube with a 200 μL pipette, and store the upper plasma in a new centrifuge tube at -80°C; add 10 mL of PBS buffer at room temperature to each tube, centrifuge at 400 g for 20 min, remove the supernatant, add 5 mL of PBS buffer at room temperature to each tube, centrifuge at 400 g for 20 min, and count the number of cells using a hemacytometer; centrifuge to remove the supernatant, use Trizol to dissolve the separated lymphocytes according to the number of cells, and store at -80°C;

[0025] 5) The lymphocytes stored at -80°C were taken out to extract total RNA, which was reverse transcribed to generate a cDNA library, and the VHH gene was obtained by nested PCR amplification to construct a VHH cDNA library; the VHH fragment was recovered by enzyme digestion and connected with the phage expression vector pCombo3 to form a recombinant phage vector, and the recombinant phage vector was then electroporated into Escherichia coli TG1 competent cells for amplification, and VHH was displayed on the surface of the phage with the help of a helper phage to form a VHH phage library, and the library capacity and library diversity of the phage library were detected.

[0026] Wherein, the step (3) is specifically as follows:

[0027] 1) Preparation of recombinant proteins for solid phase panning

[0028] The target gene was amplified using the pGEM-NPPB plasmid as a template, and the pFuse-IL2-BNP-human Fc2 eukaryotic expression plasmid was constructed by overlap extension PCR. After successful sequencing, the plasmid was extracted in large quantities and transfected into the HEK293 mammalian suspension expression system to express the recombinant protein. The target protein was then purified by acid washing using rProtein A affinity chromatography filler, verified by SDS-PAGE and Western-blot, and used as a coating protein for solid phase panning after the protein concentration was determined and stored at -80°C for future use.

[0029] 2) Solid phase panning of nanobodies based on phage display technology

[0030] The purified recombinant BNP-human Fc2 was coated on an ELISA plate, and the nanoantibodies were selected by successive rounds of pressure application. After four rounds of "adsorption-elution-amplification" selection, the VHH phages that specifically bound to the recombinant BNP-human Fc2 protein were highly enriched.

[0031] Wherein, the step (4) is specifically as follows:

[0032] 1) After DNA sequencing, the candidate positive sequence was synthesized through sequence analysis to construct the PET22b-BNPVHH-his expression vector, and 10 μL of the PET22b-BNPVHH-his positive plasmid was transformed into Rosetta (DE3) competent cells.

[0033] Pick the bacteria and place them in 6 mL of LB liquid medium containing ampicillin resistance, culture at 37°C, 220 rpm for 12-15 hours, take out the culture and place it at 4°C for later use;

[0034] 2) Take a clean 3L conical flask, prepare 2L of LB liquid culture medium, and sterilize it by high pressure at 121℃ for 30min. After cooling, add 2mL of ampicillin to a final concentration of 100μg / mL, add 2mL of activated bacterial solution to the 2L culture medium, OD=0.6-0.8, and culture at 37℃ and 220rpm for about 6-8 hours. When the OD value of the bacterial solution is 0.6, induce expression with IPTG at a final concentration of 0.5mM at 16℃ for 11h, centrifuge, discard the supernatant, keep the bacterial pellet, take a small amount of bacterial pellet for Western-Blot identification of target protein expression, resuspend the bacterial pellet in 40mL PBS, centrifuge after ultrasonic treatment, discard the pellet, and keep the supernatant containing the target protein for later use;

[0035] (3) Ni Sepharose excel affinity chromatography medium was then used to purify the target protein in the supernatant, and SDS-PAGE and Western were used to verify the purification of the target protein.

[0036] Wherein, the step (5) specifically comprises: performing specific identification of the purified VHH by Western assay; and verifying the binding ability of the purified VHH with the recombinant protein by Biacore assay.

[0037] The nanobody targeting BNP of the present invention can be used to prepare a nanobody BNP rapid detection kit.

[0038] Compared with the prior art, the outstanding effects of the present invention are:

[0039] The present invention obtains a high-affinity nano antibody targeting BNP, and can provide a tool for clinical disease diagnosis and treatment through large-scale in vitro expression and modification, which has important commercial value.

[0040] Western results showed that the nanobody can specifically bind to the BNP recombinant protein, and Biacore test results showed that the binding KD of the nanobody to the recombinant BNP protein was 11.9 nM. It can be seen that the nanobody targeting BNP of the present invention can effectively bind to BNP and can play an important role in in vitro and in vivo detection and diagnosis and treatment.

[0041] The nanoantibody targeting BNP and its preparation method and application according to the present invention are further described below in conjunction with the accompanying drawings and specific examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Schematic diagram of traditional antibodies, heavy chain antibodies and nanobodies.

[0043] Figure 2 Schematic diagram of the overall process of the preparation method of nanoantibodies targeting BNP.

[0044] Figure 3 The figure is a schematic diagram of a specific process for preparing a nanobody targeting BNP.

[0045] Figure 4 This is the PCR identification diagram of PET32a-BNP-6his prokaryotic expression plasmid.

[0046] Figure 5 The results are the expression and identification of BNP-6his immunogen.

[0047] Figure 6 The results of expression and Ni affinity purification of BNP-6his recombinant protein; wherein, M: protein molecular weight standard, 1: BNP 16℃ induced expression sample, 2: BNP AKTA purification effluent sample, 3-9: imidazole elution effluent sample.

[0048] Figure 7 This is the result of BNP-6his alpaca immune serum antibody titer determination (serum: 1:14000).

[0049] Figure 8 is the capacity of cDNA library and phage library.

[0050] Fig. 9 This is the PCR identification diagram of the pFuse-IL2-BNP-human Fc2 eukaryotic expression plasmid.

[0051] Fig.10 The results are the expression and Western-blot identification of BNP-human Fc2 recombinant protein.

[0052] Fig.11 This is the SDS-PAGE image of the purified BNP-human Fc2 recombinant protein sample.

[0053] Fig.12 The recovery rate of the solid phase panning library of nanobodies based on phage display technology.

[0054] Fig.13This is the indirect ELISA identification result of the induced expression of nanoantibodies after four rounds of selection.

[0055] Fig.14 This is the SDS-PAGE diagram of the prokaryotic expression and purification of the BNP-targeting nanobody, where M is the protein molecular weight standard, and 1-9 is the imidazole elution effluent sample.

[0056] Fig.15 This is a Western-blot identification diagram of nanoantibodies targeting BNP.

[0057] Fig.16 This is a Western-blot identification diagram of BNP nanobody as primary antibody and BNP-human Fc2 recombinant protein.

[0058] Fig.17 This is the result of identifying the binding affinity between BNP-targeted nanoantibodies and BNP recombinant protein.

[0059] Fig.18 This is the result of the binding affinity identification between the commercial BNP-targeted monoclonal antibody and the BNP recombinant protein.

[0060] Fig.19 The results of SDS-PAGE identification after pET22b-BNPVHH-SA-his induced expression. M: protein molecular weight standard; 1: pET22b-BNPVHH-SA Rosetta induced expression; 2: Rosetta induced expression positive control; 3: pET22b Rosetta induced expression blank control.

[0061] Fig. 20 This is an application example of BNPVHH-SA for detecting recombinant protein BNP. DETAILED DESCRIPTION

[0062] Example 1 Nanobodies targeting BNP

[0063] A nano antibody targeting BNP, wherein the amino acid sequences of its CDR1, CDR2 and CDR3 are CDR1: GRTFGRMG, CDR2: SIFWSSGGAIYADSVKG, and CDR3: ADTPPLGKYDY, as shown in SEQ ID NOs: 1-3, respectively.

[0064] The amino acid sequence of the nanobody is

[0065] QLQLVESGGGLVQAGDSLRLSCAASGRTFGRMGWFRQAPGKDREWVASIFWSSGGAIYAD

[0066] SVKGRFTISRDNAKNTAYLQMNRLKPEDTAAYYCAADTPPLGKYDYWGQGTQVTVSSAHHSEDPS, as shown in SEQ ID NO:4.

[0067] Example 2 Preparation of Nanobodies Targeting BNP

[0068] like Figure 2-3 As shown, the preparation method of the nano antibody targeting BNP comprises the following specific steps:

[0069] 1. Preparation of BNP Immunogen

[0070] The target gene was amplified using the pGEM-NPPB plasmid as a template, and then recovered by enzyme digestion and connected with the PET32a vector to construct the prokaryotic expression vector PET32a-BNP-6his. Figure 4 As shown, after successful sequencing, a large amount of plasmid was extracted and transformed into Rosetta (DE3) competent cells. The bacteria were picked and shaken until the OD value of the bacterial solution was 0.6, and then induced to express with a final concentration of 0.5 mM IPTG at 16°C for 11 h. Figure 5 As shown, after Western-blot verification of expression, the supernatant was discarded by centrifugation, and the bacterial pellet was treated with ultrasound. Then, the target protein was purified using Ni Sepharose excel affinity chromatography filler from Cytiva and AKATA instrument, as shown in FIG. Figure 6 As shown, the purity was verified by SDS-PAGE, the protein concentration was determined and used as an immunogen, and stored at -80°C for future use.

[0071] 2. Animal Immunization Process

[0072] 1. Preparation of immunogens: Mix 0.5 mg of the purified BNP recombinant protein with Freund's adjuvant and emulsify it in a volume of less than 2 mL. Store the homogeneous mixture formed by the emulsification of antigen and adjuvant at 4°C for later use.

[0073] 2. Alpaca immunization: Select the alpaca and make sure the animal is suitable. Record the ear number and start the immunization experiment. Each time, inject subcutaneously on the left and right sides of the alpaca's buttocks, inject 2 points on each side, and inject 0.4mL of mixed antigen at each point. Observe for half an hour after immunization to confirm that the alpaca is in good condition and has no discomfort symptoms. Immunize once every 2 weeks, for a total of 4 immunizations. The results of BNP-6his alpaca immune serum antibody titer determination are as follows Figure 7 shown.

[0074] 3. Blood collection: Blood was collected from the alpaca's neck vein before each immunization. 10 mL of blood was collected each time, and the serum was separated and stored at -80°C for later use. 100 mL of peripheral blood was collected 5 days after the last immunization to separate lymphocytes.

[0075] 4. Lymphocyte separation: First add 5mL of cell separation solution to a 15mL centrifuge tube, and then slowly add 5mL of blood. Be careful and slow when adding blood to prevent the blood and separation solution from mixing. After that, precool the centrifuge, centrifuge at 400g for 30min, observe the blood separation in the centrifuge tube, and use a 200μL pipette to carefully pipette out the cotton-like upper immune cells in the middle into a new 15mL centrifuge tube. The upper plasma is stored in a new centrifuge tube and stored at -80℃. Add 10mL of PBS buffer at room temperature to each tube and centrifuge at 400g for 20min. Remove the supernatant, add 5mL of PBS buffer at room temperature to each tube, and centrifuge at 400g for 20min. Use a hemocytometer to count the number of cells. Remove the supernatant, use RNAiso Plus to dissolve the separated lymphocytes according to the number of cells, and store at -80℃.

[0076] 3. Preparation of Nanobody cDNA Library

[0077] The total RNA was extracted from the lymphocytes stored at -80℃, and reverse transcription was used to generate a cDNA library. The VHH gene was obtained by nested PCR amplification to construct a VHH cDNA library. The VHH fragment was recovered by enzyme digestion and connected with the phage expression vector pCombo3 to form a recombinant phage vector. The recombinant phage vector was then electroporated into Escherichia coli TG1 competent cells for amplification. With the help of helper phage, VHH was displayed on the surface of the phage to form a VHH phage library, and the library capacity and library diversity of the phage library were tested. Figure 8 shown.

[0078] 4. Solid phase panning and prokaryotic expression identification based on phage display technology

[0079] 1. Preparation of recombinant proteins for solid phase panning

[0080] (1) Construction of the eukaryotic expression vector pFuse-IL2-BNP-human Fc2

[0081] The target gene was amplified using the pGEM-NPPB plasmid as a template, and the pFuse-IL2-BNP-human Fc2 eukaryotic expression plasmid was constructed by overlap extension PCR technology, such as Fig. 9 As shown, plasmid was extracted in large quantities after successful sequencing.

[0082] (2) Transfection of HEK293 mammalian suspension expression system to express recombinant protein, such as Fig.10 As shown, after the expression was verified by Western-blot experiment, the target protein was then purified by eluting with rProtein A affinity chromatography filler in a glycine solution at pH = 2.5, as shown in FIG. Fig.11As shown, the purification effect was verified by SDS-PAGE. After the protein concentration was determined, it was used as the coating protein for solid phase panning and stored at -80°C for future use.

[0083] 2. Solid-phase panning of nanoantibodies based on phage display technology

[0084] (1) Dilute BNP-human Fc2 recombinant protein with coating solution (10 μg / well in the first round, 8 μg / well in the second round, 5 μg / well in the third round, and 1 μg / well in the fourth round), 100 μL per well, and incubate at 4°C overnight.

[0085] (2) The next day, wash three times with PBST, each time for 2 min.

[0086] (3) Add 5% skim milk to the ELISA plate for blocking for 2 h, 300 μL per well.

[0087] (4) Wash the plate three times with PBST, 2 min each time.

[0088] (5) Pre-block the phage library (1x10 11 pfu / well), added to the ELISA plate and incubated for 2 h. 100 μL per well was used as a negative control without protein.

[0089] (6) Wash the plate with 0.05% PBST for 2 min each time, and wash the plate 10 times (5 PBST washes are added for each additional round of panning), and wash the plate 3 times with PBS for 2 min each time.

[0090] (7) Add 100 μL of 0.1 M triethylamine to each well for elution, and add 100 μL of pH 7.4 Tris-HCL for neutralization. Transfer the eluate to a 1.5 mL EP tube.

[0091] (8) Take 10 μL of the eluted phage and dilute it in 5 gradients (10 1-5 Add 90 μL of TG1 bacterial solution with OD600 of 0.5-0.6 to each EP tube and bathe in 37°C water for 15 min.

[0092] (9) Spread the bacterial solution of each gradient onto an ampicillin-resistant 2×YT plate, incubate the plate upside down overnight at 37°C, and count the number of single colonies on the plate to calculate the titer.

[0093] (10) At the same time, the remaining phage eluate was added to 10 mL of bacterial solution with an OD600 of 0.5-0.55, and allowed to stand at room temperature for half an hour. 0.1% Amp resistance was added and cultured for 30 minutes at 37°C and 250 rpm. 100 μL of helper phage was added and allowed to stand at room temperature for half an hour. Centrifuged at 8000 rpm for 10 minutes, and the precipitate was transferred to 100 mL 2×YT containing 0.1% ampicillin and kanamycin resistance and cultured overnight at 37°C and 220 rpm. The phage was concentrated the next day for the next round of panning.

[0094] After four rounds of panning of nanoantibodies by applying pressure one after another, VHH phages that specifically bind to the recombinant protein BNP-human Fc2 were highly enriched. The recovery rate of the solid phase panning library of nanoantibodies based on phage display technology is as follows: Fig.12 shown.

[0095] 3. Cultivate the single colonies output from four rounds of panning and induce the expression of nanoantibody crude extracts

[0096] (1) Take the plate coated with the elution solution from the fourth round, randomly select 95 phage clones, mark them as Nb1-Nb95, and culture them statically at 37°C overnight.

[0097] (2) Take 10 μL of the above bacterial solution and transfer it to 2xYT medium (1 mL / well) in a 96-deep-well plate and culture it to the logarithmic phase. Add 50% sterile glycerol to the remaining bacterial solution, shake well and store at -80°C.

[0098] (3) Add IPTG at a final concentration of 0.2 mM and induce expression at 37°C and 230 rpm for 11 h.

[0099] (4) Centrifuge at 4000 rpm and 4°C for 15 min and freeze the cells at -20°C for 30 min.

[0100] (5) After returning to room temperature, add PBS to resuspend the cells, 1 mL / well, and shake at 300 rpm at 4°C for 30 min.

[0101] (6) Centrifuge at 4000 rpm and 4°C for 10 min. The resulting supernatant is the crude nanobody extract.

[0102] 4. Indirect ELISA to detect the reactivity of crude extracts of nanobodies with recombinant BNP protein (such as Fig.13 (shown)

[0103] (1) Dilute the recombinant protein BNP-human Fc2 with coating solution, 400 ng / well, 100 μL / well, and incubate at 4°C overnight.

[0104] (2) The next day, wash three times with PBS, each time for 2 min.

[0105] (3) Add 5% skim milk to the ELISA plate for blocking for 2 h, 300 μL per well.

[0106] (4) Wash the plate three times with PBST, 2 min each time.

[0107] (5) Add the crude extract of the nanobody in step 3 as the primary antibody to the ELISA plate, 100 μL / well, and incubate at 37°C for 2 h.

[0108] (6) Wash the plate three times with PBST, 2 min each time.

[0109] (7) Add Anti-HA-HRP antibody as secondary antibody, 100 μL / well, and incubate at 37°C for 1 h.

[0110] (8) Wash the plate three times with PBST, 2 min each time.

[0111] (9) Add TMB colorimetric solution, 100 μL / well, and react at 37°C

[0112] (10) Add 2 M sulfuric acid to stop the reaction, 50 μL / well, and read the OD450 nm value.

[0113] (11) After culturing the positive phage, the bacterial solution is sent for sequencing and sequence analysis.

[0114] 5. Prokaryotic expression and purification of nanobodies

[0115] (1) After DNA sequencing, the candidate positive sequence was synthesized through sequence analysis to construct the PET22b-BNPVHH-his expression vector. 10 μL of the PET22b-BNPVHH-his positive plasmid was transformed into Rosetta (DE3) competent cells, the bacteria were picked, and placed in 6 mL of LB liquid culture medium containing ampicillin resistance, cultured at 37°C, 220 rpm, for 12 to 15 hours, and the culture was taken out and placed at 4°C for use.

[0116] (2) Take a clean 3L conical flask, prepare 2L of LB liquid culture medium and sterilize it by high pressure at 121°C for 30min. After cooling, add 2mL of ampicillin to a final concentration of 100μg / mL. Add 2mL of activated bacterial solution (OD=0.6-0.8) to the 2L culture medium and culture at 37°C and 220 rpm for about 6-8 hours. When the OD value of the bacterial solution is 0.6, induce expression with IPTG at a final concentration of 0.5mM at 16°C for 11h, centrifuge, discard the supernatant, retain the bacterial pellet, take a small amount of the bacterial pellet for Western-Blot identification of the expression of the target protein, resuspend the bacterial pellet in 40mL of PBS, ultrasonicate and centrifuge, discard the pellet and retain the supernatant containing the target protein for later use.

[0117] (3) Then, the target protein in the supernatant was purified using Ni Sepharose excel affinity chromatography filler from Cytiva with the aid of an AKATA instrument, and the purification of the target protein was verified by SDS-PAGE and Western blotting. Figure 14-15 shown.

[0118] 6. Identification of purified nanobodies

[0119] (1) Specific identification of purified VHH by Western assay, such as Fig.16 shown.

[0120] (2) The binding affinity between the purified VHH and the recombinant protein was verified by Biacore assay, and a commercial BNP nanobody (HyTest Anti-BNP) was used as a control. Figure 17-18 ,From the results, it can be seen that the binding ability of the selected nano-antibodies to recombinant proteins is better than that of traditional antibodies.

[0121] Example 3 ELISA application example of BNP-VHH fusion biotin (SA) detection of recombinant protein BNP

[0122] 1. Construct the plasmid PET22b-BNPVHH-SA-his expression vector, take 10 μL of the positive plasmid and transform it into Rosetta (DE3) competent cells, pick the bacteria, put them into 6 mL of LB liquid culture medium containing ampicillin resistance, culture at 37°C 220 rpm for 12 to 15 hours, take out the culture and place it at 4°C for use.

[0123] 2. Take a clean 300mL conical flask, prepare 200mL of LB liquid culture medium, and sterilize it at 121℃ for 30min. After cooling, add 200μL of ampicillin to a final concentration of 100μg / mL. Add 1mL of activated bacterial solution (OD=0.6-0.8) to the 200mL culture medium, and culture at 37℃ and 220rpm for about 6-8 hours. When the OD value of the bacterial solution is 0.6, induce expression with IPTG at a final concentration of 0.5mM at 16℃ for 11h, centrifuge, discard the supernatant, keep the bacterial precipitate, take a small amount of bacterial precipitate for SDS-PAGE identification of the target protein expression, such as Fig.19 As shown, the bacterial pellet was resuspended in 10 mL PBS, and after ultrasonic treatment, centrifuged, the pellet was discarded and the supernatant containing the target protein was reserved for later use.

[0124] 3. Then, the target protein in the supernatant was purified using Ni Sepharose excel affinity chromatography filler from Cytiva with the aid of an AKATA instrument, and the purified target protein was stored at -80°C.

[0125] 4. ELISA detection of recombinant protein BNP using BNPVHH-SA as the primary antibody

[0126] (1) Dilute the recombinant protein BNP-human Fc2 with coating solution, 200 ng / well, 100 μL / well, and incubate at 4°C overnight.

[0127] (2) The next day, wash three times with PBS, each time for 2 min.

[0128] (3) Add 5% skim milk to the ELISA plate for blocking for 2 h, 300 μL per well.

[0129] (4) Wash the plate three times with PBST, 2 min each time.

[0130] (5) 2 μg of BNPVHH-SA was diluted in series to 100 μL / well and incubated at 37°C for 2 h.

[0131] (6) Wash the plate three times with PBST, 2 min each time.

[0132] (7) Add Biotin-HRP, 100 μL / well, and incubate at 37°C for 1 h.

[0133] (8) Wash the plate three times with PBST, 2 min each time.

[0134] (9) Add TMB colorimetric solution, 100 μL / well, and react at 37°C.

[0135] (10) Add 2 M sulfuric acid to stop the reaction, 50 μL / well, and read the OD450 nm value.

[0136] The results are as follows Fig. 20 As shown, the BNP nanoantibodies obtained by screening can be used to construct a BNP detection kit.

[0137] The embodiments described above are merely descriptions of preferred implementation modes of the present invention and are not intended to limit the scope of the present invention. Without departing from the design of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the scope of protection determined by the claims of the present invention.

Claims

1. A nanobody targeting BNP, Features: The amino acid sequences of its CDR1, CDR2 and CDR3 are CDR1: GRTFGRMG, CDR2: SIFWSSGGAIYADSVKG, CDR3: ADTPPLGKYDY, as shown in SEQ ID NOs: 1-3, respectively.

2. The nanobody targeting BNP according to claim 1, Features: The amino acid sequence thereof is QLQLVESGGGLVQAGDSLRLSCAASGRTFGRMGWFRQAPGKDREWVASIFWSSGGAIYADSVKGRFTISRDNAKNTAYLQMNRLKPEDTAAYYCAADTPPLGKYDYWGQGTQVTVSSAH HSEDPS, as shown in SEQ ID NO:

4.

3. A method for preparing a nanobody targeting BNP according to claim 1 or 2, It is characterized in that The following steps are involved: (1) constructing a prokaryotic expression vector and expressing the recombinant protein using the Escherichia coli prokaryotic expression system; (2) using the prepared recombinant protein to immunize alpacas to prepare a nanoantibody library; (3) Solid-phase panning of nanobodies using a phage display system; (4) obtaining the nanobody sequence by sequencing and then performing prokaryotic expression and identification; (5) The nanoantibodies with high affinity binding to BNP protein were obtained through Western and Biacore identification.

4. The method for preparing a nano antibody targeting BNP according to claim 3, Features: The step (1) specifically comprises the following steps: using pGEM-NPPB plasmid as a template to amplify the target gene, recovering the target gene by enzyme digestion and then connecting it with the PET32a vector to construct a prokaryotic expression vector PET32a-BNP-6his, extracting the plasmid after successful sequencing, transforming it into Rosetta (DE3) competent cells, picking bacteria, shaking the bacteria until the OD value of the bacterial solution is 0.6, inducing the expression of the target protein with IPTG at a final concentration of 0.5 mM at 16° C. for 11 h, discarding the supernatant after centrifugation, treating the bacterial pellet with ultrasound, and then purifying the target protein using Ni Sepharose excel affinity chromatography filler, verifying it by SDS-PAGE and Western-blot, using the protein concentration as an immunogen after determination, and storing it at -80° C. for future use.

5. The method for preparing a nano antibody targeting BNP according to claim 4, It is characterized in that The step (2) is specifically: 1) Preparation of immunogen: The purified BNP recombinant protein was mixed with Freund's adjuvant for emulsification, and the homogeneous mixture formed by the emulsification of antigen and adjuvant was stored at 4°C for future use; 2) Alpaca immunization: Select the alpacas and ensure that the animals are suitable. After recording the ear number, start the immunization experiment; inject subcutaneously on the left and right sides of the alpaca's buttocks each time, inject 2 points on each side, and inject 0.4mL of emulsified antigen at each point; observe for half an hour after immunization to confirm that the alpaca is in good condition and has no discomfort symptoms; immunize once every 2 weeks, for a total of 4 immunizations; 3) Blood collection: Blood was collected from the alpaca's neck vein before each immunization. 10 mL of blood was collected each time, and the serum was separated and stored at -80°C for later use. 100 mL of peripheral blood was collected 5 days after the last immunization to separate lymphocytes. 4) Lymphocyte separation: first add 5 mL of lymphocyte separation solution to a 15 mL centrifuge tube, then slowly add 5 mL of blood; be careful and slow when adding blood to prevent the blood and separation solution from mixing, centrifuge at 400 g for 30 min, carefully pipette the cotton-like upper immune cells in the middle into a new 15 mL centrifuge tube with a 200 μL pipette, and store the upper plasma in a new centrifuge tube at -80°C; add 10 mL of PBS buffer at room temperature to each tube, centrifuge at 400 g for 20 min, remove the supernatant, add 5 mL of PBS buffer at room temperature to each tube, centrifuge at 400 g for 20 min, and count the number of cells using a hemacytometer; The supernatant was removed by centrifugation, and the separated lymphocytes were dissolved using TRIZOL according to the cell number and stored at -80°C; 5) The lymphocytes stored at -80°C were taken out to extract total RNA, which was reverse transcribed to generate a cDNA library, and the VHH gene was obtained by nested PCR amplification to construct a VHH cDNA library; the VHH fragment was recovered by enzyme digestion and connected with the phage expression vector pCombo3 to construct a recombinant phage vector, and the recombinant phage vector was then electroporated into Escherichia coli TG1 competent cells for amplification, and VHH was displayed on the surface of the phage with the help of a helper phage to form a VHH phage library, and the library capacity and library diversity of the phage library were detected.

6. The method for preparing a nanobody targeting BNP according to claim 5, It is characterized in that The step (3) is specifically: 1) Preparation of recombinant proteins for solid phase panning The target gene was amplified using the pGEM-NPPB plasmid as a template, and the pFuse-IL2-BNP-human Fc2 eukaryotic expression plasmid was constructed by overlap extension PCR. After successful sequencing, the plasmid was extracted in large quantities and transfected into the HEK293 mammalian suspension expression system to express the recombinant protein. The target protein was then purified by acid washing using rProtein A affinity chromatography filler, verified by SDS-PAGE and Western-blot, and used as a coating protein for solid phase panning after the protein concentration was determined and stored at -80°C for future use. 2) Solid phase panning of nanobodies based on phage display technology The purified recombinant BNP-human Fc2 was coated on an ELISA plate, and the nanoantibodies were selected by pressurization in successive rounds. After four rounds of "adsorption-elution-amplification" selection, the VHH phages that specifically bound to the recombinant BNP-human Fc2 protein were highly enriched.

7. The method for preparing a nanobody targeting BNP according to claim 6, It is characterized in that The step (4) is specifically as follows: 1) After DNA sequencing, the candidate positive sequence was synthesized through sequence analysis to construct the PET22b-BNPVHH-his expression vector, 10 μL of the PET22b-BNPVHH-his positive plasmid was transformed into Rosetta (DE3) competent cells, the bacteria were picked, and placed in 6 mL of LB liquid culture medium containing ampicillin resistance, 37°C 220 rpm, cultured for 12 to 15 hours, and the culture was taken out and placed at 4°C for use; 2) Take a clean 3L conical flask, prepare 2L of LB liquid culture medium, and sterilize it by high pressure at 121℃ for 30min. After cooling, add 2mL of ampicillin to a final concentration of 100μg / mL, add 2mL of activated bacterial solution to the 2L culture medium, OD=0.6-0.8, and culture at 37℃ and 220rpm for about 6-8 hours. When the OD value of the bacterial solution is 0.6, induce expression with IPTG at a final concentration of 0.5mM at 16℃ for 11h, centrifuge, discard the supernatant, keep the bacterial pellet, take a small amount of bacterial pellet for Western-Blot identification of target protein expression, resuspend the bacterial pellet in 40mL PBS, centrifuge after ultrasonic treatment, discard the pellet, and keep the supernatant containing the target protein for later use; (3) Ni Sepharose excel affinity chromatography medium was then used to purify the target protein in the supernatant, and SDS-PAGE and Western were used to verify the purification of the target protein.

8. The method for preparing a nano antibody targeting BNP according to claim 7, Features: The step (5) specifically includes: performing specific identification of the purified VHH by Western assay; and verifying the binding ability of the purified VHH with the recombinant protein by Biacore assay.

9. Use of the nanobody targeting BNP according to claim 1 or 2 in the preparation of a nanobody BNP rapid detection kit.

Citation Information

Cited By

  • Preparation method of genetically modified human bone marrow mesenchymal stem cells and application of genetically modified human bone marrow mesenchymal stem cells in treatment of nervous system diseases

    CN120173888A

  • Preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treatment of nervous system diseases

    CN120173888B